![Jump to content [Access key 'm']](/siteware/cleardot.gif){kind=small}
Home 
R&D
R&D We are generating several families of anticancer drugs that act on the cell cycle, including Cyclin Dependent kinase (CDK) and Aurora Kinase (AK) inhibitors. We are advancing three of our anticancer drug candidates, sapacitabine, seliciclib and CYC116 through in-house research and development activities. We have eight further novel drug series, five for cancer, one for inflammatory kidney disease, one for HIV/AIDS and one for Type 2 Diabetes.
Our approach to drug discovery and development relies on proprietary genomic technology to identify gene targets, which are then progressed by means of structure-based design techniques through to the development stage.
View a comprehensive list of Publications relating to our work.
Cyclacel is currently evaluating three oncology drug candidates in clinical trials: sapacitabine (CYC682), seliciclib (CYC202) and CYC116.
